Eksenatid
Eksenatid (INN, Byetta, Bydureon) agonist je glukagonu sličnog peptida-1 (GLP-1 agonist). On pripada grupi mimetika inkretina. Ovaj lek je odobren aprila 2005. za lečenje dijabetes melitusa tipa 2.[1][2][3]
 | |
| Klinički podaci | |
|---|---|
| Prodajno ime | Byetta, Byetta (Amylin/Eli Lilly) |
| Drugs.com | Monografija |
| Način primene | Subkutano |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 2,4 h |
| Izlučivanje | Renalno |
| Identifikatori | |
| CAS broj | 141758-74-9  |
| ATC kod | A10BX04 (WHO) |
| DrugBank | DB01276 |
| Hemijski podaci | |
| Formula | C184H282N50O60S |
| Molarna masa | 4186.6 |
Reference уреди
- ^ Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG: Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005 Oct 18;143(8):559-69. PMID 16230722
- ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709
. PMID 21059682. doi:10.1093/nar/gkq1126.
- ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
Literatura уреди
- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze уреди
 | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |
